Stratos Christianakis, MD
Rheumatology · Pasadena, CANPI 1831114008
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $840 of the $1,374 with a category attached, or 61.1%. Janssen Scientific Affairs, LLC accounts for 72.1% of it on its own, with 4 other manufacturers making up the rest. 2024 is the largest year on record at $1,224, more than ten times the $23 reported in 2022. That places this record below the midpoint for rheumatology clinicians in CA, where the typical reported total is $1,724.
Across 12 payments — averaging $114.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Scientific Affairs, LLC$990
- Sanofi$132
- Novartis$119
- AbbVie$88
- GSK$45
Across 1 payment — averaging $5000.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$5K
What the payments were for
- Consulting fees$84061%
- Food & beverage$53439%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Janssen Scientific Affairs, LLC | 2 | $990 |
| Sanofi | 1 | $132 |
| Novartis | 2 | $119 |
| AbbVie | 4 | $88 |
| GSK | 3 | $45 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,374 in reported general payments places this provider in the 45th percentile of 808 rheumatology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ActharCorticotropin | 15 | $796,760 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 76 | $678,912 |
| TremfyaGuselkumab | 35 | $461,578 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 33 | $438,899 |
| OtezlaApremilast | 64 | $315,361 |
| Enbrel SureclickEtanercept | 38 | $285,203 |
| Humira(Cf) PenAdalimumab | 33 | $216,336 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 12 | $140,582 |
| KevzaraSarilumab | 27 | $108,759 |
| Cimzia (2 Pack)Certolizumab Pegol | 16 | $97,231 |
| EnbrelEtanercept | 18 | $89,940 |
| SotyktuDeucravacitinib | 14 | $88,013 |
| OrenciaAbatacept | 16 | $86,901 |
| BenlystaBelimumab | 13 | $59,476 |
| ActemraTocilizumab | 16 | $36,744 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| SanofiKevzara | $132 | $108,75927 claims |
| GSKBenlysta | $45 | $59,47613 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 808 rheumatology providers in California.
Other rheumatology in Pasadena
- Sudhakar TumuluriSan Francisco$2.8M
- Ara DikranianSan Diego$2.2M
- Orrin TroumSanta Monica$1.8M
- Robin DoreTustin$1.5M
- Samy MetyasCovina$1.3M
- Rhonda LambertSan Mateo$1.1M
- William ShielMission Viejo$924K
- Mark BoriginiDowney$920K
- Adam KreitenbergTarzana$863K
- Roger KornuTustin$802K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.